Meet the Leadership

Patricia M. LoRusso

Patricia M. LoRusso, D.O., Principal Investigator

Patricia M. LoRusso, D.O. - Principal Investigator, Associate Director of Innovative Medicine, Yale Cancer Center

Patricia M. LoRusso, DO, widely-regarded as a leading expert on developing new cancer drugs through clinical trials, will join Yale Cancer Center in August as a Professor of Medicine and Associate Director of Innovative Medicine at Yale Cancer Center.

LoRusso brings more than 25 years of expertise in medical oncology, drug development, and early phase clinical trials. Prior to her Yale appointment, she served in numerous leadership roles at Wayne State University’s Barbara Karmanos Cancer Institute, most recently as director of the Phase I Clinical Trials Program and of the Eisenberg Center for Experimental Therapeutics.

"Pat LoRusso is a pre-eminent leader in early phase drug development, and she joins the cancer center at a time during which we have committed to accelerating the process of getting new drugs to patients," said Thomas J. Lynch, MD, director of Yale Cancer Center and physician-in-chief at Smilow Cancer Hospital at Yale-New Haven. "She will help the center continue to make significant contributions to the global cancer problem."

LoRusso has served as co-chair of the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP) Investigational Drug Steering Committee. She also served on the scientific committee of the American Association for Cancer Research (AACR), the education and scientific committees of the American Society of Clinical Oncology (ASCO), numerous peer-reviewed study sections, and NCI committees. She has garnered numerous awards, including the 1999 Heroes of Breast Cancer Award; 2004 Bennett J. Cohen Educational Leadership Award for Medical Research, 2008 NCI Michaele C. Christian Oncology Development Lectureship and Award; the 2014 Targeted Anticancer Therapies (TAT) Honorary Award; and will receive the 2014 Michigan State University Distinguished Alumni Award.  She was recently honored as one of the 2014 Massachusetts General Hospital Cancer Center’s “One Hundred” individuals and organizations recognized for their dedication in making a difference in the fight against cancer. LoRusso is a former editor of Investigational New Drugs, is currently on the editorial board for Clinical Cancer Research, and is a reviewer for several journals. She has authored more than 200 articles on cancer research in peer-reviewed journals, and written multiple book chapters.

“My primary mission is to make a difference in human lives, and one of the ways to do this is by bringing the very latest therapies to patients through clinical trials,” LoRusso said. “Yale Cancer Center has great research, great leadership, and a passionate group of scientists and physicians dedicated to fighting cancer, and this is where I want to apply my skills and passion.”

Roy S. Herbst, MD, PhD, chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital, and associate director of the cancer center’s Translational Research Program, called LoRusso a “truly transformational” leader.

“Bringing new drugs into clinical trials - and ultimately to FDA approval - is no easy feat, and Pat has the proven ability to do this. The global cancer community has seen her achieve this time and again,” Herbst said. 

“Pat joining our team is going to make a huge impact on how we grow our research program and help our patients.”

Jeffrey M. Trent, Ph.D., F.A.C.M.G., Principal Investigator

Jeffrey M. Trent, Ph.D., F.A.C.M.G., Principal Investigator

Jeffrey M. Trent, Ph.D., F.A.C.M.G., Principal Investigator

Jeffrey M. Trent, Ph.D., F.A.C.M.G., is president and research director of the Translational Genomics Research Institute (TGen) and the Van Andel Research Institute (VARI).

Trent is a recognized expert in the area of human cancer genetics. He has held numerous faculty appointments including at the University of Arizona, the University of Michigan, Johns Hopkins University and Arizona State University. He is a diplomat of the American College of Medical Genetics, and is a member of the Mayo Clinic Comprehensive Cancer Center. He served on the Board of Directors of the American Association for Cancer Research, and is a member of the American Association for the Advancement of Science, the American Society of Human Genetics and the American Society of Clinical Oncology. Trent is the author of over 300 manuscripts in the medical literature, has received numerous honors and awards, and has served on the editorial boards of over a dozen medical journals.

Trent previously served as director of the Division of Intramural Research of the National Human Genome Research Institute at the National Institutes of Health (NIH). Under his guidance from 1993 to 2002, the division became an internationally recognized research center in the field of human genetics. Following his tenure at the NIH, Trent became the founding president and research director of The Translational Genomics Research Institute (TGen) in Phoenix, Ariz., a position he holds today. In February 2009, he also joined Van Andel Research Institute in Grand Rapids, Michigan.